DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for pontocerebellar hypoplasia type 9 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePontocerebellar hypoplasia type 9 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pontocerebellar hypoplasia type 9 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
adenosine monophosphate deaminase 2 (AMPD2) — AMPD2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ampdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8HU6 · 2.33 Å · ligand ADENOSINE MONOPHOSPHATE (AMP). Experimental structure, not a prediction.
What the evidence adds up to
Pontocerebellar hypoplasia type 9 is a rare autosomal recessive neurodevelopmental disorder caused by mutation in the AMPD2 gene. A 2024 case report describes a 21-month-old boy with homozygous missense mutations in AMPD2 whose MRI showed an eight-configured midbrain and hypoplasia of the brainstem and cerebellum. The authors call these neuroradiological features pathognomonic for PCH9 but provide no data on any drug treatment or intervention.
A 2019 report describes a child with a heterozygote mutation in exon 8 of TSEN54 and in exon 1 of EXOSC3, a genetic combination not previously documented. Clinical features included seizures, feeding and swallowing disorders, strabismus, kyphoscoliosis, poor balance and coordination, mental retardation, severe speech impairment, hypotonia, and distinctive dysmorphic features. MRI showed microgyria, pontocerebellar hypoplasia, corpus callosum hypoplasia, and T4 rachischisis. EEG showed epileptic discharges and disorganised cortical rhythm. EMG was normal. Uncontrolled seizures made the child’s condition unstable and he required palliative care. No drug is named and no treatment outcome is reported.
A 2011 study of 169 patients from 141 families tested for mutations in TSEN54, TSEN2, TSEN34, and RARS2 found that 106 patients had mutations in one of these genes. TSEN54 mutations were strongly correlated (P < 0.0005) with a dragonfly-like cerebellar pattern on MRI, where the cerebellar hemispheres are flat and severely reduced while the vermis is relatively spared. Clinically, TSEN54 mutations were associated with dyskinesia or dystonia and variable spasticity; nonsense or splice site mutations produced a more severe phenotype with perinatal symptoms, ventilator dependency, and early death. RARS2 mutations were linked to pontocerebellar hypoplasia type 1 with elevated cerebrospinal fluid lactate. Again, no drug treatment is mentioned.
What is missing: no clinical trial has tested any drug for PCH9 or for the TSEN54/EXOSC3 combination described. There are no data on survival, response rates, or sample sizes for any pharmacological intervention. The field lacks funding for preclinical drug screening, a standardised natural history study to define endpoints, and any attempt at patient stratification by mutation type or neuroradiological pattern.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cureus · 2024 · 1 citations · open access
Pontocerebellar Hypoplasia Type 9: A Case Study Highlighting Distinctive Magnetic Resonance Imaging Features
AbstractPontocerebellar hypoplasia type 9 (PCH9) is a rare, autosomal, recessive, neurodevelopmental disorder caused by a mutation in the AMPD2 gene. Despite its rarity, it presents distinctive clinical and neuroradiological features. Diagnosing it is challenging yet crucial for appropriate management. We describe a 21-month-old boy with clinical and neuroradiological manifestations of the diagnosis, including characteristic signs such as an eight-configured midbrain and hypoplasia of the brainstem and cerebellar structures. Genetic evaluation confirmed homozygous missense mutations in the AMPD2 gene. This case highlights the pathognomonic neuroradiological features of pontocerebellar hypoplasia type 9 that point toward diagnosis.
P95 The undeclared new type of pontocerebellar hypoplasia
Abstract<h3>Background</h3> Pontocerebellar hypoplasia (PCH) refers to a group of severe neurodegenerative disorders affecting growth and function of the brainstem and cerebellum, resulting in serious neurological consequences or psychomotor delay. Different types are classified according to the clinical picture and the spectrum of pathologic changes. <h3>Method</h3> Clinical, genetic, molecular, encephalographic, radiological, pathological and survival data were gathered. <h3>Results</h3> The patient report presents the medical history of a pontocerebellar hypoplasia (PCH) child, which unrepresented in previous case histories. Our patient has a heterozygote mutation in 8 exon gene TSEN54 and in 1 exon in gene EXOSC3. It is important to note that such a mutation in TSEN54, however, in different exons is presented in PCH type 2A, PCH type 4 and PCH type 5 and a mutation in gene EXOSC3 is demonstrated in PCH1B. We compared all known PCH types (19 PCH types) and tried to find correlations between this child’s features and those associated with the other one. This case tries to resolve the diagnostic issues related to the combination of features of these different types simultaneously in one child. Clinical features include seizures, feeding and swallowing disorders, strabismus, kyphoscoliosis, poor balance and coordination, mental retardation, severe speech impairment, hypotonia. Our patient had some phenotype peculiarities, such as: brachycephalia, protruding brow arcs, preauricular excrescence, medial eyebrow flare, hypoplasia of the lower face, large nose, eyelids ptosis. The morphological changes of this case were microgyria, pontocerebellar hypoplasia, and corpus colosum hypoplasia. Moreover, an MRI confirmed TH4 rachischisis, and an ultrasound revealed thymomegaly and septal defects. An EEG demonstrated slow flashes with high-amplitude. In the frontal leads we can see epileptic discharges and periods of disorganization of cortical rhythm. EMG results were normal. Blood test showed no abnormalities. Uncontrolled seizures made the child’s condition unstable and he needed palliative care. <h3>Conclusion</h3> Therefore, our investigation continues to determine whether the child has a pontocerebellar hypoplasia (PCH) with undeclared molecular karyotype or has a combination of PCH type 2A, PCH type 4 and PCH type 5.
Zurich Open Repository and Archive (University of Zurich) · 2011 · 0 citations · open access
Clinical, neuroradiological and genetic findings in pontocerebellar hypoplasia
AbstractPontocerebellar hypoplasia is a group of autosomal recessive neurodegenerative disorders with prenatal onset. The common characteristics are cerebellar hypoplasia with variable atrophy of the cerebellum and the ventral pons. Supratentorial involvement is reflected by variable neocortical atrophy, ventriculomegaly and microcephaly. Mutations in the transfer RNA splicing endonuclease subunit genes (TSEN54, TSEN2, TSEN34) were found to be associated with pontocerebellar hypoplasia types 2 and 4. Mutations in the mitochondrial transfer RNA arginyl synthetase gene (RARS2) were associated with pontocerebellar hypoplasia type 6. We studied a cohort of 169 patients from 141 families for mutations in these genes, of whom 106 patients tested positive for mutations in one of the TSEN genes or the RARS2 gene. In order to delineate the neuroradiological and clinical phenotype of patients with mutations in these genes, we compared this group with 63 patients suspected of pontocerebellar hypoplasia who were negative on mutation analysis. We found a strong correlation (P < 0.0005) between TSEN54 mutations and a dragonfly-like cerebellar pattern on magnetic resonance imaging, in which the cerebellar hemispheres are flat and severely reduced in size and the vermis is relatively spared. Mutations in TSEN54 are clinically associated with dyskinesia and/or dystonia and variable degrees of spasticity, in some cases with pure generalized spasticity. Nonsense or splice site mutations in TSEN54 are associated with a more severe phenotype of more perinatal symptoms, ventilator dependency and early death. In addition, we present ten new mutations in TSEN54, TSEN2 and RARS2. Furthermore, we show that pontocerebellar hypoplasia type 1 together with elevated cerebrospinal fluid lactate may be caused by RARS2 mutations.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
